Status:
APPROVED_FOR_MARKETING
Expanded Access for IMMU-132
Lead Sponsor:
Gilead Sciences
Conditions:
Metastatic Triple-Negative Breast Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.
Eligibility Criteria
Inclusion
- \-
Exclusion
- \-
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04320693
Last Update
August 19 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.